Relay Therapeutics, Inc. Common Stock (RLAY) Financials
Key financial figures for Relay Therapeutics, Inc. Common Stock (Q3 2026).
Relay Therapeutics, Inc. reported revenue of $0.00 for Q3 FY2026. The company posted a net loss of $81.7 million, or -$0.37 per share. Free cash flow for the period was -$63.9 million. The figures above are as filed, and the full income statement, balance sheet and cash flow history for Relay Therapeutics, Inc. are on the SentiSense financials page.
- Revenue
- $0
- Net Income
- -$82M
- EPS
- $-0.37
- Total Assets
- $902M
- Operating Cash Flow
- -$64M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q3 FY2026 | $0 | -$82M | -$0.37 | -$64M | |
| Q2 FY2026 | $350K | -$84M | -$0.41 | -25949.71% | -$54M |
| Q1 FY2026 | $3M | -$73M | -$0.41 | -2619.67% | -$51M |
| Q4 FY2025 | $7M | -$55M | -$0.32 | -866.16% | -$45M |
| Q3 FY2025 | $0 | -$74M | -$0.43 |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $15M | -$276M | -$1.61 | -1971.59% | -$236M |
| FY2024 | $10M | -$338M | -$2.36 | -3722.07% | -$251M |
| FY2023 | $26M | -$342M | -$2.79 | -1460.11% | -$304M |
Frequently asked questions
What was Relay Therapeutics, Inc.'s revenue last quarter?
Relay Therapeutics, Inc. reported revenue of $0.00 for Q3 FY2026.
Is Relay Therapeutics, Inc. profitable?
Not in its most recent reported period. Relay Therapeutics, Inc. reported a net loss of $81.7 million for Q3 FY2026.
How much free cash flow did Relay Therapeutics, Inc. generate?
Relay Therapeutics, Inc. generated free cash flow of -$63.9 million in Q3 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Relay Therapeutics, Inc. Common Stock on SentiSense, with up to forty quarters and twenty fiscal years of history.